Reality Check on Dry Eye
Market access for dry eye treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 40% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: The FDA in August 2019 required Kala Pharmaceuticals, Inc. to complete an additional clinical trial of KPI-121 0.25%, the company's candidate for the temporary relief of the signs and symptoms of dry eye disease
- Key Findings: Contracting for preferred formulary status is expected to expand as new agents are approved. Many payers do not allow coverage for compounded products, so Klarity-C may have access issues
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.